ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway

Xu, Peng; Wang, Handong*; Pan, Hao*; Chen, Jiakai; Deng, Chulei南方医科大学; 南京大学; 1
Cancer Chemotherapy and Pharmacology2022-2DOI: 10.1007/s00280-021-04380-5
14被引8阅读
引用收藏
分享

摘要

Purpose Anlotinib protects against carcinogenesis through the induction of autophagy and apoptosis. The current study evaluated the role and molecular mechanisms of anlotinib in glioblastoma, and the effects of anlotinib in combination with temozolomide (TMZ). Methods Cell Counting Kit-8 and colony-forming assays were used to evaluate cell viability. Cell migration and invasion were assessed by wound-healing, Transwell migration, and Matrigel invasion assays. Cellular apoptosis and cell cycle analysis were determined by flow cytometry. Angiogenesis was assessed using human umbilical vein endothelial cells (HUVECs). Vascular endothelial growth factor A (VEGFA) was measured by enzyme-linked immunosorbent assay. Protein expression was determined by western blotting or immunofluorescence staining. The in vivo anti-glioblastoma effect was assessed with live imaging of tumor xenografts in nude mice. Results Anlotinib restricted the proliferation, migration, and invasion of glioblastoma cells in a dose-dependent manner. Tumor supernatant from glioblastoma cells treated with anlotinib inhibited angiogenesis in HUVECs. Anlotinib induced autophagy in glioblastoma cells by increasing Beclin-1 and microtubule-associated protein 1 light chain 3B (LC3B) levels. Mechanistically, anlotinib inhibited the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3)/VEGFA signaling pathway. STAT3 inhibition by S3I-201 decreased VEGFA and suppressed cellular proliferation and movement. TMZ enhanced the anti-glioblastoma ability of anlotinib. Finally, anlotinib inhibited tumor growth and JAK2/STAT3/VEGFA signaling in xenografts. Conclusion Anlotinib exerts anti-glioblastoma activity possibly through the JAK2/STAT3/VEGFA signaling pathway. TMZ potentiated the anti-glioblastoma effect of anlotinib via the same signaling pathway, indicating the potential application of anlotinib as a treatment option for glioblastoma.

学科与关键词

关键词
AnlotinibGlioblastomaJAK2STAT3VEGFA signaling pathwayProliferationMigrationInvasion
相关
加载中…
  • Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
    Xu, Qingsheng; Huang, Kaiyuan; Meng, Xiangqi; Weng, Yuxiang; Zhang, Luyuan; Bu, Linghao; Zheng, Xiujue; Cai, Jinquan*; Zhan, Renya*; Chen, Qun*Clinical Cancer Research, 2023, 29(19): 3859-3866.
  • CCL2-targeted ginkgolic acid exerts anti-glioblastoma effects by inhibiting the JAK3-STAT1/PI3K-AKT signaling pathway
    Chen, Xi; Zhu, Mingwei; Zou, Xiaomeng; Mao, Yingxuan; Niu, Jiamei; Jiang, Jian; Dong, Tianxiu; Shi, Ying; Yang, Xiuhua*; Liu, Pengfei*Life Sciences, 2022, 311: 121174.被引 2
  • A phase II study of anlotinib combined with temozolomide in the treatment of patients with recurrent glioblastoma.
    Xu, Qingsheng; Chen, Qun; Zheng, Xiujue; Cai, Jinquan; Zhan, RenyaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Chemotherapy and Pharmacology
发表日期
2022-02
卷期
第 89 卷, 第 2 期
页码
183-196
DOI
10.1007/s00280-021-04380-5
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
Science Foundation of Jiangsu Province, China [ZDXKB2016023]

作者

  • X

    Xu, Peng (第一作者)

    southeast univ

  • W

    Wang, Handong (通讯)

    southeast univ

查看全部 5 位作者收起作者
  • P

    Pan, Hao (通讯)

    southeast univ

  • C

    Chen, Jiakai

    nanjing univ

  • D

    Deng, Chulei

    1 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417